TopicNeuroscience

glioblastoma

Explore Neuroscience Browse all domains

Content Overview

43Total items

40ePosters

3Seminars

Latest

SeminarNeuroscience

Astrocytes release glutamate by regulated exocytosis in health and disease

Vladimir Parpura

Distinguished Professor Zhejiang Chinese Medical University and Director of the International Translational Neuroscience Research Institute, Hangzhou, P.R. China

Jun 5, 2025

Astrocytes release glutamate by regulated exocytosis in health and disease Vladimir Parpura, International Translational Neuroscience Research Institute, Zhejiang Chinese Medical University, Hangzhou, P.R. China Parpura will present you with the evidence that astrocytes, a subtype of glial cells in the brain, can exocytotically release the neurotransmitter glutamate and how this release is regulated. Spatiotemporal characteristic of vesicular fusion that underlie glutamate release in astrocytes will be discussed. He will also present data on a translational project in which this release pathway can be targeted for the treatment of glioblastoma, the deadliest brain cancer.

SeminarNeuroscience

MBI Webinar on preclinical research into brain tumours and neurodegenerative disorders

Ekaterina (Caty) Salimova and Ms Sanjeevini Babu Reddiar

Apr 13, 2022

WEBINAR 1 Breaking the barrier: Using focused ultrasound for the development of targeted therapies for brain tumours presented by Dr Ekaterina (Caty) Salimova, Monash Biomedical Imaging Glioblastoma multiforme (GBM) - brain cancer - is aggressive and difficult to treat as systemic therapies are hindered by the blood-brain barrier (BBB). Focused ultrasound (FUS) - a non-invasive technique that can induce targeted temporary disruption of the BBB – is a promising tool to improve GBM treatments. In this webinar, Dr Ekaterina Salimova will discuss the MRI-guided FUS modality at MBI and her research to develop novel targeted therapies for brain tumours. Dr Ekaterina (Caty) Salimova is a Research Fellow in the Preclinical Team at Monash Biomedical Imaging. Her research interests include imaging cardiovascular disease and MRI-guided focused ultrasound for investigating new therapeutic targets in neuro-oncology. - WEBINAR 2 Disposition of the Kv1.3 inhibitory peptide HsTX1[R14A], a novel attenuator of neuroinflammation presented by Sanjeevini Babu Reddiar, Monash Institute of Pharmaceutical Sciences The voltage-gated potassium channel (Kv1.3) in microglia regulates membrane potential and pro-inflammatory functions, and non-selective blockade of Kv1.3 has shown anti-inflammatory and disease improvement in animal models of Alzheimer’s and Parkinson’s diseases. Therefore, specific inhibitors of pro-inflammatory microglial processes with CNS bioavailability are urgently needed, as disease-modifying treatments for neurodegenerative disorders are lacking. In this webinar, PhD candidate Ms Sanju Reddiar will discuss the synthesis and biodistribution of a Kv1.3-inhibitory peptide using a [64Cu]Cu-DOTA labelled conjugate. Sanjeevini Babu Reddiar is a PhD student at the Monash Institute of Pharmaceutical Sciences. She is working on a project identifying the factors governing the brain disposition and blood-brain barrier permeability of a Kv1.3-blocking peptide.

SeminarNeuroscienceRecording

Sparks, flames, and inferno: epileptogenesis in the glioblastoma microenvironment

Jeff Noebels

Baylor College of Medicine

Oct 7, 2020

Glioblastoma cells trigger pharmacoresistant seizures that may promote tumor growth and diminish the quality of remaining life. To define the relationship between growth of glial tumors and their neuronal microenvironment, and to identify genomic biomarkers and mechanisms that may point to better prognosis and treatment of drug resistant epilepsy in brain cancer, we are analyzing a new generation of genetically defined CRISPR/in utero electroporation inborn glioblastoma (GBM) tumor models engineered in mice. The molecular pathophysiology of glioblastoma cells and surrounding neurons and untransformed astrocytes are compared at serial stages of tumor development. Initial studies reveal that epileptiform EEG spiking is a very early and reliable preclinical signature of GBM expansion in these mice, followed by rapidly progressive seizures and death within weeks. FACS-sorted transcriptomic analysis of cortical astrocytes reveals the expansion of a subgroup enriched in pro-synaptogenic genes that may drive hyperexcitability, a novel mechanism of epileptogenesis. Using a prototypical GBM IUE model, we systematically define and correlate the earliest appearance of cortical hyperexcitability with progressive cortical tumor cell invasion, including spontaneous episodes of spreading cortical depolarization, innate inflammation, and xCT upregulation in the peritumoral microenvironment. Blocking this glutamate exporter reduces seizure load. We show that the host genome contributes to seizure risk by generating tumors in a monogenic deletion strain (MapT/tau -/-) that raises cortical seizure threshold. We also show that the tumor variant profile determines epilepsy risk. Our genetic dissection approach sets the stage to broadly explore the developmental biology of personalized tumor/host interactions in mice engineered with novel human tumor mutations in specified glial cell lineages.

glioblastoma

Latest

Astrocytes release glutamate by regulated exocytosis in health and disease

MBI Webinar on preclinical research into brain tumours and neurodegenerative disorders

Sparks, flames, and inferno: epileptogenesis in the glioblastoma microenvironment

SYNERGISTIC CO-TARGETING OF DNA GLYCOSYLASE NEIL1 AND G-QUADRUPLEX STRUCTURES UNCOVERS NOVEL THERAPEUTIC OPPORTUNITIES IN GLIOBLASTOMA

BISDEMETHOXYCURCUMIN MODULATES MGMT ASSOCIATED CHEMORESISTANCE IN GLIOBLASTOMA CELL LINES WHILE EXHIBITING MINIMAL TOXICITY TO PRIMARY ASTROCYTES

THE EFFECT OF STABILIZING OR INHIBITING HYPOXIA-INDUCIBLE FACTORS ON THE TREATMENT OF GLIOBLASTOMA CELLS WITH METFORMIN

A FIRST-IN-CLASS BRAIN-PENETRANT THERANOSTIC PROBE TARGETING THE APELIN RECEPTOR FOR GLIOBLASTOMA

A PRECLINICAL STUDY EXPLORING THE PHARMACOLOGICAL INTERACTION BETWEEN TEMOZOLOMIDE CHEMOTHERAPY AND ANTIDEPRESSANT TREATMENTS IN A RAT GLIOBLASTOMA MODEL

IDENTIFICATION OF NOVEL COMBINATORIAL TREATMENTS TO DRIVE GLIOBLASTOMA STEM CELLS OUT OF STEMNESS IN 2D AND 3D ORGANOID MODELS

SPATIOTEMPORAL GLIAL DYNAMICS IN GLIOBLASTOMA

MEMBRANE DISRUPTION OF THE GANGLIOSIDE-NEUROPLASTIN-PMCA NETWORK DRIVES CALCIUM DYSREGULATION IN GLIOBLASTOMA

THE IMPACT OF HEALTHY FECAL MATERIAL TRANSPLANTATION ON GLIOBLASTOMA

CANONICAL HISTONE H3 VARIANTS ARE LINKED TO CELL CYCLING IN GLIOBLASTOMA

SPATIOTEMPORAL DISTRIBUTION OF CIRCADIAN CLOCK PROTEINS AND THEIR IMPACT ON GENE EXPRESSION IN GLIOBLASTOMA <EM>IN VITRO</EM> MODELS

MODULATION OF CALCIUM OSCILLATIONS IN GLIOBLASTOMA: AN ELECTROPHYSIOLOGICAL APPROACH

TETRASPANIN CD9: FROM NEURAL STEM CELLS TO GLIOBLASTOMA MICROENVIRONMENT CONTROL

ESTABLISHMENT OF A ZEBRAFISH XENOGRAFT ASSAY TO ANALYZE GLIOBLASTOMA CELLS-MICROENVIRONMENT INTERACTIONS AND THERAPEUTIC RESISTANCE

AN ORTHOTOPIC GL261–GCAMP6S MOUSE MODEL TO STUDY GLIOBLASTOMA GROWTH AND TUMOUR‑RELATED EPILEPSY

CELL FUSION–MEDIATED DELIVERY OF BIOMOLECULES FOR GLIOBLASTOMA TREATMENT

CHARACTERIZING THE MIRNA IMPRINTOME IN ADULT NEURAL STEM CELLS AND GLIOBLASTOMA

NATURAL ALKALOID BOLDINE REDUCES PROLIFERATION IN GLIOBLASTOMA CELL LINES AND PRIMARY HUMAN CULTURES

THE ROLE OF GLYCINE AS MEDIATOR OF GUT MICROBIOTA ALTERATION IN A GLIOBLASTOMA CONTEXT

SYNERGY OF CONCURRENT PI3K-MAPK INHIBITION IN GLIOBLASTOMA STEM CELLS: VIABILITY, MORPHOLOGICAL CHANGES AND <EM >IN VIVO</EM> HISTOPATHOLOGY

MIRO1, A KEY ACTOR IN THE REGULATION OF MITOCHONDRIAL TRANSFER TO GLIOBLASTOMA CELLS

SPATIALLY RESTRICTED IMMATURE NEURONAL PROGRAMS DRIVE FUNCTIONAL CONNECTIVITY IN GLIOBLASTOMA

ADDRESSING MITOCHONDRIAL DYNAMICS IN INTERCELLULAR TRANSFER TO GLIOBLASTOMA

GLIOBLASTOMA INVASION REORGANIZES NETWORK STRUCTURE AND INFORMATION FLOW IN <EM>IN VITRO </EM>NEURONAL NETWORKS

TEMPERATURE-MEDIATED BIOELECTROMAGNETIC CONTROL OF HUMAN GLIOBLASTOMA PROLIFERATION

UNDERSTANDING GLIOBLASTOMA INVASION USING 3D BRAIN ORGANOIDS

LINEAGE REPROGRAMMING OF HUMAN GLIOBLASTOMA CELLS INTO NEURONS USING PATIENT-DERIVED TUMOR ORGANOIDS

EPHRINA5–EPH SIGNALLING MODULATES GLIOBLASTOMA MIGRATION AND PROLIFERATION VIA TRANSCRIPTIONAL REGULATION OF ADHESION GENES

DIAPH3 as a survival prognostic factor in glioblastoma patients

Effect of polybrene on different glioblastoma subtypes

Elucidating the role of VAMP7-dependent late endosomal autophagic secretion in glioblastoma progression

Ethanol extract of Vanilla planifolia stem reduced PAK6 expression and induced cell death in glioblastoma cells

Interaction between M2 muscarinic receptors and β-1 arrestin in glioblastoma cell lines: Effects mediated by orthosteric and dualsteric agonists

Investigating the role of hyperphosphorylated tau in both neurodegenerative disease and glioblastoma using adult human organotypic slice cultures

Involvement of glioblastoma-derived extracellular vesicles in promoting endothelial cell remodelling: Implications for glioblastoma tumour progression

LRIG1 regulates the balance between proliferation and quiescence in glioblastoma stem cells

Machine learning identifies potential anti-glioblastoma small molecules

Modulating voltage-gated sodium channels to enhance differentiation and sensitize glioblastoma cells to chemotherapy

The morphology of glioblastoma stem cells impacts tumour progression

Parvalbumin interneurons protect peritumoral tissue from glioblastoma growth